Ibrutinib

Overview

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling, which may result to decreased growth of cancer cells.

SparkCures ID 31
Developed By Pharmacyclics
Generic Name Ibrutinib
Additional Names Imbruvica, PCI-32765
Treatment Classifications
  • Bruton's Tyrosine Kinase (BTK) Inhibitor

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.